Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.12. | Cellev8 Nutrition Inc: Groundbreaking Collaboration: Vivos Therapeutics and Cellev8 Nutrition Join Forces to Address Sleep Apnea and Oxidative Stress | 248 | ACCESSWIRE | WELLINGTON, FL and HIGHLANDS RANCH, CO / ACCESSWIRE / December 10, 2024 / Cellev8 Nutrition Inc. (OTC Pink:CELV) and Vivos Therapeutics, Inc. today announced a strategic joint marketing venture aimed... ► Artikel lesen | |
VIVOS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
27.11. | Vivos Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14.11. | Vivos Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
08.10. | InvestorNewsBreaks - Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces AMA Issues CPT Codes, Coverage for Vivos CARE Oral Medical Devices | 2 | iNVEZZ.com | ||
08.10. | Vivos Therapeutics, Inc: Vivos Therapeutics Granted CPT Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association | 84 | GlobeNewswire (Europe) | LITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a medical technology company specializing in the development and commercialization... ► Artikel lesen | |
20.09. | Vivos Therapeutics, Inc. - 8-K, Current Report | 10 | SEC Filings | ||
19.09. | TinyGemsBreaks - Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct Offering | 1 | iNVEZZ.com | ||
19.09. | Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today | 1 | Benzinga.com | ||
19.09. | Vivos Therapeutics announces $4.3M registered direct offering of common stock | 3 | Seeking Alpha | ||
18.09. | Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children | 1 | Benzinga.com | ||
18.09. | Vivos Therapeutics Gets FDA 510(k) Clearance To Treat Pediatric Sleep Apnea, Snoring; Stock Up | 1 | RTTNews | ||
18.09. | Vivos Therapeutics, Inc: Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring | 276 | GlobeNewswire (Europe) | Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos' DNA appliance now approved... ► Artikel lesen | |
12.09. | Vivos Therapeutics kündigt neuen Aktienoptionsplan und Änderungen in Führungsverträgen an | 1 | Investing.com Deutsch | ||
12.09. | Vivos Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
20.08. | Ascendiant sees 180% upside in Vivos Therapeutics shares amid revenue rebound | 3 | Investing.com | ||
16.08. | Earnings call: Vivos Therapeutics sees revenue and enrollment growth | 1 | Investing.com | ||
15.08. | Vivos Therapeutics GAAP EPS of -$0.60, revenue of $4.1M | 1 | Seeking Alpha | ||
15.08. | Vivos Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
14.08. | Vivos Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
14.08. | Vivos Therapeutics, Inc: Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update | 269 | GlobeNewswire (Europe) | Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ECKERT & ZIEGLER | 44,580 | +0,41 % | Eckert&Ziegler-Aktionäre aufgepasst: Dieses SCHOCKIERENDE Kursziel könnte den Kurs jetzt in den Keller schicken! | ||
INTUITIVE SURGICAL | 502,90 | -0,02 % | $100 Invested In Intuitive Surgical 5 Years Ago Would Be Worth This Much Today | ||
ROKU | 76,87 | -0,53 % | This Roku Ultra streaming device gave my TV 4K superpowers - and it's on sale right now | ||
SERNOVA | 0,146 | -3,95 % | Sernova Corp.: Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025 | ||
SYNLAB | 11,220 | -0,53 % | Ikonisys SA: Ikonisys to Start Collaboration with SYNLAB Italy to Introduce Ikoniscope in Pathology Laboratories | Regulatory News:
Ikonisys (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis... ► Artikel lesen | |
DEXCOM | 76,90 | +0,17 % | Kurs von Dexcom steigt etwas (75,3822 €) | Am US-amerikanischen Aktienmarkt liegt der Anteilsschein von Dexcom aktuell im Plus. Zuletzt zahlten Investoren für die Aktie 78,35 US-Dollar. Heute hat sich an der US-amerikanischen Börse die Dexcom-Aktie... ► Artikel lesen | |
NUGEN MEDICAL DEVICES | 0,052 | -1,14 % | NuGen Medical: Erster landesweiter Verkauf startet jetzt…. | ||
PLUS THERAPEUTICS | 0,998 | -3,67 % | Plus Therapeutics Inc.: Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium | ||
CARDINAL HEALTH | 113,70 | +0,26 % | Is Cardinal Health Stock Underperforming the Dow? | ||
INVITAE | 0,110 | 0,00 % | Invitae Aktie: Drastischer Kursverfall trotz Umsatzwachstum | Der Aktienkurs des Biotechnologieunternehmens Invitae ist in den letzten Tagen stark eingebrochen. Am 8. September fiel der Kurs um 25% auf 0,0003 USD, was einen besorgniserregenden Trend fortsetzt.... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,934 | +0,65 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density | 1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a Poster Spotlight Session During... ► Artikel lesen | |
EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
UNIDOC HEALTH | 0,310 | 0,00 % | UniDoc Health Corp. blickt zurück auf ein Jahr des Wachstums und der Innovation | - Strategische Partnerschaften und KI-Integration positionieren UniDoc als E-Health-Lösung
VANCOUVER, British Columbia, 17. Dezember 2024 / IRW-Press / UniDoc Health Corp.... ► Artikel lesen | |
FRESENIUS | 33,200 | -0,84 % | Fresenius SE Aktie: Positiver Umsatztrend! | Die Fresenius SE-Aktie zeigt sich im aktuellen Handelsverlauf an der XETRA mit wechselhafter Tendenz. Nach einem Handelsstart bei 34,92 EUR bewegte sich der Kurs im Tagesverlauf zwischen verschiedenen... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 52,10 | -0,72 % | Nach Siemens-Energy-Boom: Startet als nächstes die Siemens-Healthineers-Aktie durch? | Ein starkes Schlussquartal und ein optimistischer Ausblick des Medizintechnikers Siemens Healthineers sollten der Aktie genug Rückenwind liefern, auf den Anleger gehebelt setzen können. So funktioniert's.... ► Artikel lesen |